Tango Therapeutics, Inc. (TNGX)

Every figure this model derived for TNGX, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 351,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 1,013,990,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 1,031,671,000 AssetsCurrent 2026-06-30
current liabilities 20,299,000 LiabilitiesCurrent 2026-06-30
equity 1,024,532,000 StockholdersEquity 2026-06-30
ocf -143,896,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 53,811,000 Revenues 2026-06-30
sbc 40,294,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up TNGX on one particular measure came for.

RatioValue
cash operating margin-174.93
current ratio50.82
current ratio reported50.82
deferred revenue growth-100.0
dilution pct6.36
fcf margin-268.06
growth cv1.61
operating margin-253.38
owner earnings margin-342.94
revenue growth121.47
revenue growth per share108.23
roic-1021.75
rule of 40-131.91
sbc pct revenue74.88

What to be careful about

What this model itself distrusts about TNGX's figures. Written by the derivation as it ran, not added afterwards.